

FCR 8

Office of the President
December 7, 2010

Members, Board of Trustees:

PATENT ASSIGNMENT REPORT

Recommendation: that the Board of Trustees accept the patent assignment report for the period July 1 through September 30, 2010.

Background: The March 4, 1997 meeting of the Board of Trustees authorized the University of Kentucky Research Foundation to conduct all future copyright and patent filings and prosecutions. Quarterly reports on patent and copyright applications are to be submitted to the Finance Committee of the Board.

Action taken: Approved Disapproved Other _____

PATENT ASSIGNMENT
QUARTERLY FOR THE PERIOD THROUGH SEPTEMBER 30, 2010

Patents

The following assignments on behalf of the Board of Trustees of the University of Kentucky Research Foundation have been executed:

- 1. U.S. Patent Application Serial Number: (to be assigned)**
Filed: August 20, 2010
Title: “Ultra-small RNAs as toll-like receptor antagonists”
Inventor: Dr. Jayakrishna Ambati (Ophthalmology)
Technical Description: This invention relates to the ability of ultra-small RNAs to act as toll-like receptors.
Summary: Macular degeneration is a leading cause of age-related blindness. At present, there are limited treatment options for the disease. The inventor has discovered compounds that inhibit the development of macular degeneration in animal models of the disease. The compounds should prove useful to slow or prevent age-related macular degeneration in humans.
- 2. U.S. Patent Application Serial Number: (to be assigned)**
Filed: September 13, 2010
Title: “Bis-quaternary ammonium salts as pain modulating agents”
Inventors: Drs. Joseph R. Holtman (Anesthesiology), Peter A. Crooks, Linda P. Dwoskin, and Elzbieta Wala (Pharmaceutical Sciences) and J. Michael McIntosh (outside inventor).
Technical Description: This invention relates to the use of bis-quaternary ammonium salts for pain modulation, treatment, reversal and/or prevention of inflammatory pain, neuropathic pain or nociceptive pain.
Summary: The financial loss due to pain has been estimated at \$100 billion per year in medical fees, decreased productivity, litigation, and pharmaceuticals. Current drugs used to treat pain either are only moderately effective or highly addictive. The inventors have developed a novel class of drugs which have been shown to decrease pain in laboratory animals and which may provide more effective pain relief without being addictive.

Patent Activities

Fiscal year to date as of September 30, 2010

Number of Patent Applications	2
Number of Patents Issued	7
Patent Receipts	\$258,840.64